College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; Health Data Research UK, London, United Kingdom.
Health Data Research UK, London, United Kingdom; Academic Unit of Ophthalmology, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, United Kingdom.
J Invest Dermatol. 2021 Sep;141(9):2109-2111. doi: 10.1016/j.jid.2021.02.744. Epub 2021 Mar 22.
Artificial intelligence (AI)-based applications have the potential to improve the quality and efficiency of patient care in dermatology. Unique challenges in the development and validation of these technologies may limit their generalizability and real-world applicability. Before the widespread adoption of AI interventions, randomized trials should be conducted to evaluate their efficacy, safety, and cost effectiveness in clinical settings. The recent Standard Protocol Items: Recommendations for Interventional Trials-AI extension and Consolidated Standards of Reporting Trials-AI extension guidelines provide recommendations for reporting the methods and results of trials involving AI interventions. High-quality trials will provide gold standard evidence to support the adoption of AI for the benefit of patient care.
人工智能（AI）为基础的应用程序有潜力提高皮肤科患者护理的质量和效率。这些技术在开发和验证方面存在独特的挑战，可能会限制其通用性和实际应用。在广泛采用 AI 干预措施之前，应进行随机试验，以评估其在临床环境中的疗效、安全性和成本效益。最近的标准议定书项目：干预试验-AI 扩展和报告试验-AI 扩展指南的建议为报告涉及 AI 干预的试验方法和结果提供了建议。高质量的试验将提供黄金标准证据，以支持采用 AI 来改善患者护理。
